Agree still think it's dragging the feet to be on own estimates seeing 2-3 years before it has drug candidates at pre-clinical stage - that's a very long tail. They really need to be pulling in deals or partnerships that put forward significant up-fronts or early stage licensing with near term milestones above penny's - that's what will crack the whip. Delivery of other company's drugs through EET probably the most lucrative if they stumble across them ? Deals with equity stakes at significant premium likewise.
Confused, page-29
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $909.8M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.3¢ | 19.0¢ | $1.029M | 5.194M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 644566 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 469271 | 6 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |